nach oben

Erschienen in:

04.11.2017 | Original Article

Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer

verfasst von: Laszló Zoltan, Robert Farkas, Andrew V. Schally, Eva Pozsgai, Andras Papp, Laura Bognár, Tamas Tornoczki, Laszlo Mangel, Szabolcs Bellyei

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

The aim of the present study was to investigate the relationship between the intensity of biomarker expression and the response to radiochemotherapy in patients with advanced esophageal squamous cell cancer (ESCC). Ninety-two patients with locally advanced ESCC were examined retrospectively. Pre-treatment tumor samples were stained for proteins SOUL, Hsp 16.2, Growth Hormone-Releasing Hormone Receptor (GHRH-R) and p-Akt using immunhistochemistry methods. Kaplan-Meier curves were used to show the relationship between intensity of expression of biomarkers and clinical parameters and 3-year OS. A significant correlation was found between high intensity staining for Hsp 16.2, p-Akt and SOUL and poor response to NRCT. Application of a higher dose of radiation and higher dose of cisplatin resulted in better clinical and histopathological responses, respectively. Among the clinical parameters, the localization of the tumor in the upper-third of the esophagus and less than 10% weight loss were independent prognostic factors for increased 3-year OS. Hsp16.2, p-Akt and SOUL are predictors of negative response to NRCT, therefore these biomarkers may become promising targets for therapy. Furthermore, level of expression of p-Akt, weight loss and the localization of the tumor are significant factors in the prediction of OS in ESCC.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. https://doi.org/10.1002/ijc.29210 CrossRef

Keighley MR (2003) Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 18(Suppl 3):7–30CrossRef

Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. The Lancet Oncology 8(6):545–553. https://doi.org/10.1016/S1470-2045(07)70172-9 CrossRefPubMed

Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials G (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. The Lancet Oncology 8(3):226–234. https://doi.org/10.1016/S1470-2045(07)70039-6 CrossRefPubMed

Hanna A, Birla R, Iosif C, Boeriu M, Constantinoiu S (2016) Benefits and Disadvantages of Neoadjuvant Radiochemotherapy (RCT) in the Multimodal Therapy of Squamous Esophageal Cancer (ESC). Chirurg 111(1):12–25

Nakajima M, Kato H (2013) Treatment options for esophageal squamous cell carcinoma. Expert Opin Pharmacother 14(10):1345–1354. https://doi.org/10.1517/14656566.2013.801454 CrossRefPubMed

Ordu AD, Nieder C, Geinitz H, Scherer V, Kup PG, Schuster T, Combs SE, Fakhrian K (2014) Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer. Anticancer Res 34(12):7255–7261PubMed

Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R (2006) Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 78(3):236–244. https://doi.org/10.1016/j.radonc.2006.01.009 CrossRef

Gillham CM, Reynolds J, Hollywood D (2007) Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation. World Journal of Surgical Oncology 5:97. https://doi.org/10.1186/1477-7819-5-97 CrossRefPubMedPubMedCentral

10.

Sarbia M, Ott N, Puhringer-Oppermann F, Brucher BL (2007) The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer 97(10):1404–1408. https://doi.org/10.1038/sj.bjc.6604037 CrossRefPubMedPubMedCentral

11.

Zhu Z, Yu W, Fu X, Sun M, Wei Q, Li D, Chen H, Xiang J, Li H, Zhang Y, Zhao W, Zhao K (2015) Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma. Journal of experimental & clinical cancer research : CR 34:95. https://doi.org/10.1186/s13046-015-0212-z CrossRef

12.

Ui T, Morishima K, Saito S, Sakuma Y, Fujii H, Hosoya Y, Ishikawa S, Aburatani H, Fukayama M, Niki T, Yasuda Y (2014) The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway. Oncol Rep 31(2):619–624. https://doi.org/10.3892/or.2013.2899 CrossRefPubMed

13.

Jin Z, Yan W, Jin H, Ge C, Xu Y (2016) Psoralidin inhibits proliferation and enhances apoptosis of human esophageal carcinoma cells via NF-kappaB and PI3K/Akt signaling pathways. Oncol Lett 12(2):971–976. https://doi.org/10.3892/ol.2016.4716 CrossRefPubMedPubMedCentral

14.

Wang X, Li X, Li C, He C, Ren B, Deng Q, Gao W, Wang B (2016) Aurora-A modulates MMP-2 expression via AKT/NF-kappaB pathway in esophageal squamous cell carcinoma cells. Acta Biochim Biophys Sin 48(6):520–527. https://doi.org/10.1093/abbs/gmw030 CrossRefPubMed

15.

Xue L, Yang L, Jin ZA, Gao F, Kang JQ, Xu GH, Liu B, Li H, Wang XJ, Liu LJ, Wang BL, Liang SH, Ding J (2014) Increased expression of HSP27 inhibits invasion and metastasis in human esophageal squamous cell carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 35(7):6999–7007. https://doi.org/10.1007/s13277-014-1946-5 CrossRef

16.

Chen JH, Chen LM, Xu LY, Wu MY, Shen ZY (2006) Expression and significance of heat shock proteins in esophageal squamous cell carcinoma. Zhonghua zhong liu za zhi [Chinese journal of oncology] 28(10):758–761

17.

Farkas R, Pozsgai E, Bellyei S, Cseke L, Szigeti A, Vereczkei A, Marton S, Mangel L, Horvath OP, Papp A (2011) Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer. Anticancer Res 31(5):1769–1775PubMed

18.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3):205–216

19.

Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11):2680–2686CrossRef

20.

Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24(28):4620–4625. https://doi.org/10.1200/JCO.2006.06.7629 CrossRef

21.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740. https://doi.org/10.1056/NEJMoa040694 CrossRef

22.

Bellyei S, Szigeti A, Boronkai A, Pozsgai E, Gomori E, Melegh B, Janaky T, Bognar Z, Hocsak E, Sumegi B, Gallyas F, Jr. (2007) Inhibition of cell death by a novel 16.2 kD heat shock protein predominantly via Hsp90 mediated lipid rafts stabilization and Akt activation pathway. Apoptosis 12 (1):97–112. doi:https://doi.org/10.1007/s10495-006-0486-x

23.

Bellyei S, Szigeti A, Pozsgai E, Boronkai A, Gomori E, Hocsak E, Farkas R, Sumegi B, Gallyas F, Jr. (2007) Preventing apoptotic cell death by a novel small heat shock protein. Eur J Cell Biol 86 (3):161–171. doi:https://doi.org/10.1016/j.ejcb.2006.12.004

24.

Szigeti A, Bellyei S, Gasz B, Boronkai A, Hocsak E, Minik O, Bognar Z, Varbiro G, Sumegi B, Gallyas F, Jr. (2006) Induction of necrotic cell death and mitochondrial permeabilization by heme binding protein 2/SOUL. FEBS Lett 580 (27):6447–6454. doi:https://doi.org/10.1016/j.febslet.2006.10.067

25.

Somji S, Sens MA, Lamm DL, Garrett SH, Sens DA (2001) Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. Cancer Detect Prev 25(1):62–75PubMed

26.

de Manzoni G, Pedrazzani C, Laterza E, Pasini F, Grandinetti A, Bernini M, Ruzzenente A, Zerman G, Tomezzoli A, Cordiano C (2005) Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results. Ann Thorac Surg 80(4):1176–1183. https://doi.org/10.1016/j.athoracsur.2005.02.048 CrossRefPubMed

27.

Pasini F, de Manzoni G, Pedrazzani C, Grandinetti A, Durante E, Gabbani M, Tomezzoli A, Griso C, Guglielmi A, Pelosi G, Maluta S, Cetto GL, Cordiano C (2005) High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Annals of oncology : official journal of the European Society for Medical Oncology 16(7):1133–1139. https://doi.org/10.1093/annonc/mdi207 CrossRef

28.

Hanna A, Birla R, Iosif C, Boeriu M, Tomsa R, Puscasu A, Constantinoiu S (2015) Evaluation of Neoadjuvant Radiochemotherapy Response (RCT) in Squamous Esophageal Cancer (ESC) and Implications in Therapeutic Conduct. Chirurg 110(3):214–223

29.

Parcellier A, Schmitt E, Brunet M, Hammann A, Solary E, Garrido C (2005) Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid Redox Signal 7(3–4):404–413. https://doi.org/10.1089/ars.2005.7.404 CrossRefPubMed

30.

Xu Y, Chen Z, Zhang G, Xi Y, Sun R, Wang X, Wang W, Chai F, Li X (2016) HSP90B1 overexpression predicts poor prognosis in NSCLC patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 37(10):14321–14328. https://doi.org/10.1007/s13277-016-5304-7 CrossRef

31.

Chang X, Zhao J, Tian F, Jiang Y, Lu J, Ma J, Zhang X, Jin G, Huang Y, Dong Z, Liu K, Dong Z (2016) Aloe-emodin suppresses esophageal cancer cell TE1 proliferation by inhibiting AKT and ERK phosphorylation. Oncol Lett 12(3):2232–2238. https://doi.org/10.3892/ol.2016.4910 CrossRefPubMedPubMedCentral

32.

Sha K, Yeh S, Chang C, Nastiuk KL, Krolewski JJ (2015) TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures. Oncotarget 6(28):25726–25740. 10.18632/oncotarget.4535 CrossRefPubMedPubMedCentral

33.

Li X, Wang S, Ren H, Ma J, Sun X, Li N, Liu C, Huang K, Xu M, Ming L (2016) Molecular correlates and prognostic value of tmTNF-alpha expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy. Cancer biology & therapy 17(6):684–692. https://doi.org/10.1080/15384047.2016.1187551 CrossRef

34.

Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL (2002) Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate 52(3):173–182. https://doi.org/10.1002/pros.10105 CrossRefPubMed

35.

Kahan Z, Arencibia JM, Csernus VJ, Groot K, Kineman RD, Robinson WR, Schally AV (1999) Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 84(2):582–589. https://doi.org/10.1210/jcem.84.2.5487 CrossRefPubMed

36.

Garcia-Fernandez MO, Schally AV, Varga JL, Groot K, Busto R (2003) The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat 77(1):15–26CrossRef

37.

Rekasi Z, Czompoly T, Schally AV, Halmos G (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A 97(19):10561–10566. https://doi.org/10.1073/pnas.180313297 CrossRefPubMedPubMedCentral

38.

Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T (2000) Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci U S A 97(19):10555–10560. https://doi.org/10.1073/pnas.180313097 CrossRefPubMedPubMedCentral

39.

Szereday Z, Schally AV, Szepeshazi K, Bajo AM, Hebert F, Halmos G, Nagy A (2003) Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. Int J Oncol 22(5):1141–1146PubMed

40.

Hohla F, Moder A, Mayrhauser U, Hauser-Kronberger C, Schally AV, Varga JL, Zarandi M, Buchholz S, Huber R, Aigner E, Ritter M, Datz C (2008) Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon. Int J Oncol 33(1):137–143PubMed

41.

Wu CC, Chang CM, Hsu TW, Lee CH, Chen JH, Huang CY, Lee CC (2016) The effect of individual and neighborhood socioeconomic status on esophageal cancer survival in working-age patients in Taiwan. Medicine 95(27):e4140. https://doi.org/10.1097/MD.0000000000004140 CrossRefPubMedPubMedCentral

42.

Koppert LB, Lemmens VE, Coebergh JW, Steyerberg EW, Wijnhoven BP, Tilanus HW, Janssen-Heijnen ML (2012) Impact of age and co-morbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer. Br J Surg 99(12):1693–1700. https://doi.org/10.1002/bjs.8952 CrossRef

43.

Kandaz M, Ertekin MV, Bilici M (2012) Retrospective analysis of patients with esophageal cancer treated with radiotherapy and/or chemoradiotherapy. Tumori 98(4):445–450. https://doi.org/10.1700/1146.12638 CrossRefPubMed

44.

Neuhof D, Neumayer F, Einbeck W, Haschemian K, Mai SK, Hochhaus A, Willeke F, Rudi J, Debus J, Wenz F (2005) Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. Acta Oncol 44(2):168–173. https://doi.org/10.1080/02841860510029563 CrossRefPubMed

45.

Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotte P, Lerebours E, Michel P (2007) Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 102(11):2557–2563. https://doi.org/10.1111/j.1572-0241.2007.01437.x CrossRefPubMed

46.

Zemanova M, Novak F, Vitek P, Pazdro A, Smejkal M, Pazdrova G, Petruzelka L (2012) Outcomes of patients with oesophageal cancer treated with preoperative chemoradiotherapy, followed by tumor resection: influence of nutritional factors. Journal of BUON : official journal of the Balkan Union of Oncology 17(2):310–316

47.

Papp A, Cseke L, Farkas R, Pavlovics G, Horvath G, Varga G, Szigeti A, Bellyei S, Marton S, Poto L, Kalmar K, Vereczkei A, Pozsgai E, Horvath OP (2010) Chemo-radiotherapy in locally advanced squamous cell oesophageal cancer--are upper third tumours more responsive? Pathol Oncol Res 16(2):193–200. https://doi.org/10.1007/s12253-009-9206-5 CrossRefPubMed

48.

Papp A, Cseke L, Pavlovics G, Farkas R, Varga G, Marton S, Poto L, Esik O, Horvath OP (2007) The effect of preoperative chemo-radiotherapy in the treatment of locally advanced squamous cell carcinoma in the upper- and middle-thirds of the esophagus. Magy Seb 60(3):123–129. https://doi.org/10.1556/MaSeb.60.2007.3.1 CrossRefPubMed

Titel: Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer
verfasst von: Laszló Zoltan
Robert Farkas
Andrew V. Schally
Eva Pozsgai
Andras Papp
Laura Bognár
Tamas Tornoczki
Laszlo Mangel
Szabolcs Bellyei
Publikationsdatum: 04.11.2017
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 1/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0342-z

Springer Medizin

Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results

Blueberry as a Potential Radiosensitizer for Treating Cervical Cancer

Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines

Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder

Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases

MicroRNA Expression in Laser Micro-dissected Breast Cancer Tissue Samples – a Pilot Study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie